IC Targets is the merger of the Norwegian life science companies Epitarget and IC Contrast in 2015. The Company is privately owned by Norwegian private and institutional investors.

The Company repositions the magnetic resonance imaging (MRI) contrast agent mangafodipir for cardiac MRI. The contrast agent allows cardiologists to precisely quantify myocyte viability after heart infarction to guide further treatment. The agent has earlier been marketed for liver imaging with an excellent safety profile. The new indication has been successfully tested in a
clinical proof-of-principle study involving 10 patients.

IC Targets also pursues opportunities within the original indication for the contrast agent mangafodipir, namely liver and pancreas MRI. Manufacturing and distribution agreements are under negotiation.

The company is based in Oslo, Norway. Oslo is not only the global home of modern contrast agents, but has also a thriving immuno-oncology

Board of Directors

Håkon Sæterøy, Executive Chairman of the Board
Mr. Håkon Sæterøy is Managing Director of Investor Corporate AS, the second largest shareholder of IC Targets AS. He is a co-founder and currently serves as CEO of Alzheimer´s diagnostics company Pre Diagnostics AS. Sæterøy was Executive Chairman of listed diagnostic company DiaGenic ASA from 2002 - 2010, Executive Chairman of drug development company Serodus ASA from 2008 - 2012 and chairman/board member of diagnostic company Skannex AS from 2008-2014.
With 30 years of experience in management, corporate finance and business development, Sæterøy has an extensive international network. He has worked with corporate finance in Norwegian investment banks for 12 years and continued the financing and M&A consultancy business in his own company Investor Corporate AS.
Sæterøy has been a shareholder and board member in several life science companies in Norway. He is a board member of Nansen Neuroscience Network (chairman from 2010 - 2012) and was a board member of Oslo Cancer Cluster (2007 - 2014).


Peter Aspelin, MD PhD, Board Member
Dr. Peter Aspelin is professor of medical radiology at the Karolinska Institutet and Karolinska University Hospital in Stockholm, Sweden. He received his medical degree from Lund University in 1971 and earned his PhD in radiology in 1976 at he same institution. In 1989 he left Lund to assume the posts of professor of radiology and chairman of the department of radiology at the Karolinska Institutet. He was subsequently appointed dean of education at the Karolinska Institutet and later served as vice president for six years. Peter’s scientific work has focused on contrast media. He has published more than 170 scientific papers. He has also served as an associate editor for European Radiology and Acta Radiologica, as well as a reviewer for a number of other journals, including the New England Journal of Medicine, European Journal of Radiology, British Journal of Radiology and The Lancet, among others.

Willy Eidsaunet, Chief Medical Officer and Board Member
Mr. Willy Eidsaunet has served 35 years within the pharmaceutical and diagnostics industry. He spent 16 years at CIBA-GEIGY from 1973 to 1989 before joining Nycomed Imaging. In the period 1992-94 Willy was Executive Vice President at Nycomed's operations in Spain, before relocating to Oslo, Norway as Senior Vice President Strategic Marketing/Medical & Regulatory Affairs (1994-97). After Nycomed’s merger with Amersham plc in 1997 and, later, after General Electric’s acquisition of Nycomed Amersham in 2004, he served as Senior Vice President of Technology Collaboration, R&D (1997-2007). Willy was the CEO of IC Contrast up to the merger with Epitarget in 2015.


Ståle C. Kvitle, Board Member
Mr. Kvitle has 20 years of experience from Medical Devices within Johnson & Johnson, Medical Devicses & Diagonstic group, both Nordic and Internationally. Currently President at DEFA Power Systems. He holds a Master in Business and Economics from BI Norwegian Business School. He brings a broad experience from sales & marketing, as well as experience from product development, licensing followed by global commercialization.

Scientific Advisors

Per Jynge, MD PhD DHC

Dr. Per Jynge is the co-inventor of ic targets’ novel use of manganese contrast agents for cardiac magnetic resonance imaging (cMRI) Per trained as general surgeon before turning to experimental surgery, physiology and pharmacology. Academic positions include lecturer at University of Tromsø (1973-81), Assistant Professor and Professor in Pharmacology & Physiology at University of Trondheim and Norwegian University of Science and Technology (NTNU, Trondheim; 1981-2008), and guest Professor in Pharmacology at University of Linköping, Sweden (2008-2014). Per received an honorary doctorate from University of Linköping in 2005. His interests are within translational research in cardiovascular pathophysiology and magnetic resonance imaging (MRI). Early research activities were related to protection of the heart during cardiac surgery and to novel x-ray contrast media, however, since 1993 Per’s research has centred on diagnostic and therapeutic uses of manganese compounds. He has published about 130 scientific papers, 2 books, and filed 8 patent applications.